Nature Reviews Drug Discovery contents February 2014 Volume 13 Number 2 pp 81-156

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2014 Volume 13 Number 2
Impact Factor 33.078 *	In this issue Comment News and Analysis Research Highlights Analysis Reviews Correspondence Also this month  Featured article: PI3K and cancer: lessons, challenges and opportunities David A. Fruman and Christian Rommel
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
FREE POSTER: Dyslipidaemia and its treatment Robert A. Hegele & Philip Barter Disorders of plasma lipid and lipoprotein metabolism can cause atherosclerotic cardiovascular disease. This poster displays the main lipid-metabolism pathways in the body, the points at which monogenetic protein mutations lead to dyslipidaemia, and the mechanisms of action of both established and novel lipid-modifying drugs.  Download the free poster now! This poster was produced with support from: Regeneron Pharmaceuticals, Inc.  and Sanofi
In this issue p81 | doi:10.1038/nrd4242 Full Text
Comment: Precompetitive activity to address the biological data needs of drug discovery Ben Sidders, Christoph Brockel, Alex Gutteridge, Lee Harland, Peter Gildsig Jansen, Robert McEwen, David Michalovich, Henrik Seidel, Bertram Weiss, Bryn Williams-Jones & Mathew Woodwark p83 | doi:10.1038/nrd4230 The efficiency and effectiveness of target selection and validation could be improved with accessible, standardized and integrated biological reference data sets. Such resources should be established through precompetitive approaches. Full Text | PDF
NEWS AND ANALYSIS		Top
2013 FDA drug approvals Asher Mullard p85 | doi:10.1038/nrd4239 Although the FDA's 27 new approvals are down from the 15-year high of 2012, the newcomers pack powerful commercial potential. PDF
NEWS IN BRIEF US biomedical R&D spending declines, Asian spending soars p91 | doi:10.1038/nrd4244 PDF
A step closer to European clinical trial reform p91 | doi:10.1038/nrd4245 PDF
Lead GPR40 agonist bites the dust p91 | doi:10.1038/nrd4246 PDF
BIOBUSINESS BRIEFS Regulatory watch: Where do new medicines originate from in the EU? Helene Lincker, Constantinos Ziogas, Melanie Carr, Nuria Porta & Hans-Georg Eichler p92 | doi:10.1038/nrd4232 PDF
PATENT WATCH Court clears the way for Nexium alternative Charlotte Harrison p94 | doi:10.1038/nrd4240 PDF
Recent patents related to PI3K p95 | doi:10.1038/nrd4241 PDF
AN AUDIENCE WITH... Mads Krogsgaard Thomsen p96 | doi:10.1038/nrd4238 Mads Krogsgaard Thomsen celebrates his twentieth anniversary of overseeing R&D at Novo Nordisk. PDF
FROM THE ANALYST'S COUCH Biosimilar competition: lessons from Europe Henry Grabowski, Rahul Guha & Maria Salgado p99 | doi:10.1038/nrd4210 Grabowski and colleagues analyse the European market uptake of biosimilar versions of two major therapeutic biologics — epoetin alfa and filgrastim — and discuss the implications for the future development of the market for biosimilars. PDF
RESEARCH HIGHLIGHTS Top Kidney disease: Targeting a faulty filter p101 | doi:10.1038/nrd4234 PDF Anticancer drugs: Curbing self-renewal of cancer-initiating cells p102 | doi:10.1038/nrd4237 PDF Phenotypic screening: A more rapid route to target deconvolution p102 | doi:10.1038/nrd4243 PDF Immunological disorders: Spotting the troublemakers p103 | doi:10.1038/nrd4251 PDF Neurodevelopmental disorders: The gut-microbiome-brain connection p104 | doi:10.1038/nrd4235 PDF IN BRIEF G protein-coupled receptors: Cloud computing gives insights into activation | Chemical genetics: Genome-wide target identification | Anticancer drugs: A novel way to hit the proteasome | Infectious disease: New leads for resistant tuberculosis PDF Drug Discovery JOBS of the week Phd Student (M / F) German Cancer Research Center (DKFZ) Postdoctoral Position in Regenerative Medicine Centro cardiologico Monzino IRCCS PhD position in Biomedical Imaging at the University of Southampton University of Southampton Lab Manager, Biomedical Genomic Core Nationwide Children's Hospital, Research Institute PhD Positions in Biomedical Optics Universidad de Murcia More Science jobs from Drug Discovery EVENT Advances in Cancer Drug Discovery 30.03.14 Cambridge, UK More science events from
ANALYSIS		Top
The role of ligand efficiency metrics in drug discovery Andrew L. Hopkins, György M. Keserü, Paul D. Leeson, David C. Rees & Charles H. Reynolds p105 | doi:10.1038/nrd4163 Ligand efficiency metrics quantify the molecular properties required to gain binding affinity for a drug target. This article discusses the application of such metrics in the selection and optimization of fragments, hits and leads, highlighting how optimizing ligand efficiency metrics based on both molecular mass and lipophilicity, when set in the context of the specific target, has the potential to increase the quality of drug candidates. Abstract | Full Text | PDF | Supplementary information
REVIEWS		Top
Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases? Henry F. Vischer, Marco Siderius, Rob Leurs & Martine J. Smit p123 | doi:10.1038/nrd4189 Herpesviruses can hijack the G protein-coupled receptor (GPCR)-mediated cellular signalling networks of their host, which subverts cellular signalling and contributes to viral pathogenesis. In this Review, the authors discuss how herpesvirus-encoded GPCRs could be promising targets in certain inflammatory and proliferative diseases. Abstract | Full Text | PDF
PI3K and cancer: lessons, challenges and opportunities David A. Fruman & Christian Rommel p140 | doi:10.1038/nrd4204 The activation of phosphoinositide 3-kinase (PI3K) signalling is nearly ubiquitous in human cancer, but inhibitors of this pathway have demonstrated only limited activity in the clinic. Here, Fruman and Rommel discuss the complexity of the PI3K signalling network in cancer, address challenges associated with therapeutic intervention and propose strategies to guide future efforts in translational and clinical research. Abstract | Full Text | PDF | Supplementary information
CORRESPONDENCE		Top
Correspondence: A new roadmap for drug development for Alzheimer's disease Robert E. Becker, Nigel H. Greig, Ezio Giacobini, Lon S. Schneider & Luigi Ferrucci p156 | doi:10.1038/nrd3842-c2 Full Text | PDF
Advertisement
Nature Biotechnology & Nature Immunology  FOCUS ON HIGH-DIMENSIONAL IMMUNE ANALYSIS  Nature Biotechnology and Nature Immunology present a series of specially commissioned articles discussing new technologies and approaches that enable more detailed and comprehensive analysis of the immune system. Register for the accompanying Webcast and live Q&A- - broadcasting on February 7th http://bit.ly/1dB5yE9   Produced with support from  Adaptive Biotechnologies
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.